<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01372982</url>
  </required_header>
  <id_info>
    <org_study_id>033/08</org_study_id>
    <nct_id>NCT01372982</nct_id>
  </id_info>
  <brief_title>Bioavailability Study of Letrozole Tablets 2.5 mg of Dr.Reddy's Under Fed Conditions</brief_title>
  <official_title>An Open Label, Balanced, Randomized, Two Treatment, Two Sequence, Two Period, Cross-Over, Single-Dose, Comparative Oral Bioavailability Study Of Letrozole 2.5 mg Tablets (Test) Of Dr.Reddy's Laboratories Ltd And Femara 2.5 mg Tablets (Reference) Of Novartis Pharmaceuticals Corporation, USA In Healthy, Post Menopausal Women Subjects Under Fed Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Reddy's Laboratories Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Reddy's Laboratories Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare bioavailability in healthy, post menopausal women
      subjects under fed conditions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An Open Label, Balanced, Randomized, Two Treatment, Two Sequence, Two Period, Cross-Over,
      Single-Dose, Comparative oral bioavailability study in healthy, post menopausal women
      subjects under fed conditions.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bioavailability based on Cmax and AUC parameters</measure>
    <time_frame>3 Months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Femara</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Letrozole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Letrozole</intervention_name>
    <description>Letrozole Tablets 2.5 mg of Dr.Reddy's Laboratories Limited</description>
    <arm_group_label>Femara</arm_group_label>
    <arm_group_label>Letrozole</arm_group_label>
    <other_name>FemaraÂ® Tablets 2.5 mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Healthy post menopausal women within the age range of 40 to 69 years.

          -  A body mass index within 18-29.9 Kg/m2

          -  The postmenopausal status should be confirmed by

          -  Serum Estradiol concentration &lt; 40 pg/mL.

          -  Serum follicle stimulating hormone FSH)concentration &gt;30 IU/L.

          -  No vaginal bleeding for at least 1 year.

          -  Given written informed consent to participate in the study.

          -  Absence of disease markers ofHIV 1 &amp; 2, hepatitis B &amp; C virus and RPR. Absence of
             significant disease or clinically significant abnormal laboratory values on laboratory
             evaluation, medical history and physical examination during the screening.

          -  A normal l2-lead ECG.

          -  A normal chest X-ray (PA view) with in six months before the date of dosing.

          -  Comprehension of the nature and purpose of the study and compliance with the
             requirement of the entire protocol.

          -  No history or no evidence of hypersensitivity/ idiosyncratic reaction to Letrozole and
             related drugs or peanut products or other ingredients of the Letrozole formulation.

          -  No history of significant systemic diseases.

          -  Non-smokers.

          -  No history of psychiatric disorders.

          -  No donation of blood (one unit or 350 mL) within 56 days prior to study check- in.

          -  No history of addiction to any recreational drug or drug dependence.

          -  No participation in any clinical study within the past 56 days.

          -  No receipt of any prescription drugs within 4 weeks or over-the-counter drugs (e.g.:
             Cold preparations, and antacid preparations vitamins and natural products used for
             therapeutic benefits) within 14 days prior to receiving the first dose of study
             medication or repeated use of drugs within the last four weeks.

          -  No history of dehydration from diarrhoea, vomiting or any other reason within a period
             of 24 hours prior to study check-in.

          -  No family history of neurological disorders.

          -  Not consumed alcohol and xanthine containing food and beverages, (chocolates, tea,
             coffee or cola drinks) cigarettes and tobacco products, for at least 48 hours, prior
             to study check in.

          -  Not consumed grape fruit containing food or beverages (mosumbi/sweet lime) or poppy
             containing foods within the 7 days prior to check-in of both periods.

          -  Negative results for drugs of abuse (Benzodiazepines, Cocaines, Opioids,
             Amphetamines,Cannabinoids and Barbiturates) in urine during the each period of study
             check-in.

          -  Negative alcohol breathe analysis during the each period of study check-in.

        Exclusion Criteria:

        Subjects incapable of understanding the informed consent.

          -  History of suggestive of breast carcinoma, endometrial carcinoma or cervical
             carcinoma.

          -  History of suggestive of deep vein thrombosis and / or undiagnosed vaginal bleeding.

          -  History of thromboembolic disorders.

          -  History of seizures.

          -  History of any other major surgical procedure in the past 3 months.

          -  History of diabetes mellitus and systemic hypertension.

          -  Past history of anaphylaxis or angioedema.

          -  History of porphyria, Dubin-Johnson, Rotor syndrome or any other hyperbilirubinemia
             syndrome.

          -  History of otosclerosis exacerbated during pregnancy.

          -  History of cardiovascular, renal, hepatic, ophthalmic,pulmonary, neurological,
             metabolic,haematological, gastrointestinal,endocrine or immunological diseases.

          -  Consumption of alcohol for more than two years, or consumption of more than three
             alcoholic drinks per day or consumption of alcohol within 48 hours prior to dosing and
             during the study {one drink is equal to one unit of alcohol [one glass wine, half pint
             beer, and one measure (one ounce) of spirit}.

          -  History of difficulty with donating blood or difficulty in accessibility of veins.

          -  An unusual or abnormal diet e.g. low sodium diet, for two weeks prior to receiving any
             medication and through out subject's participation in the study, for whatever reason
             e.g. because of fasting due to religious reasons.

          -  Any major illness in the past three months or any clinically significant ongoing
             chronic medical illness e.g. congestive heart failure, hepatitis, pancreatitis etc.

          -  If any Dysplastic changes in the Papanicolaou Smear.

          -  Female volunteers demonstrating a positive pregnancy test.

          -  Female volunteers who are currently breast-feeding.

          -  History of problem in swallowing tablet.

          -  Used an oral contraceptive containing estrogens or progesterone, or any form of
             hormonal therapy or intake of HRT and pharmacological agents known to significantly
             induce or inhibit drug metabolizing enzymes within 6 months of the start of the study.

          -  History of habituation to coffee, tea or other xanthine containing products and
             inability to withhold the intake during the-in house-stay.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>A. Jaya Chandra Reddy, FRCS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Trident Life Sciences Ltd.</affiliation>
  </overall_official>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 13, 2011</study_first_submitted>
  <study_first_submitted_qc>June 13, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 14, 2011</study_first_posted>
  <last_update_submitted>June 13, 2011</last_update_submitted>
  <last_update_submitted_qc>June 13, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 14, 2011</last_update_posted>
  <responsible_party>
    <name_title>Dr. Ramesh Mullangi -Director</name_title>
    <organization>Dr. Reddy's Laboratories Limited</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Letrozole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

